about
Botulinum toxin type B for cervical dystoniaEndovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis.Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysisPlacebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis.Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.Psychogenic non-epileptic seizures in early Huntington's disease.Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate.Autosomal dominant polycystic kidney disease and coronary artery dissection or aneurysm: a systematic review.Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis.Opicapone for the treatment of Parkinson's disease.Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.Anterior ischemic optic neuropathy and hematologic malignancy: a systematic review of case reports and case series.Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease".Clinical Trials Corner: September 2017.Botulinum toxin type A therapy for cervical dystonia.Neurofilament light protein in blood predicts regional atrophy in Huntington disease.Intracerebral hemorrhage as a manifestation of cerebral hyperperfusion syndrome after carotid revascularization: systematic review and meta-analysis.Overall Survival and Causes of Death in Neurodegeneration-An Overlooked and Underreported Theme.Quality of life in Huntington's disease: Critique and recommendations for measures assessing patient health-related quality of life and caregiver quality of life.Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.Huntington’s Disease Clinical Trials Corner: February 2018Her Aching Bones: Atypical Parathyroid Adenoma.Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and RecommendationsPhysician perception versus true efficacy of tetrabenazine for Huntington’s diseaseAdverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosisFrequency of post-stroke electroencephalographic epileptiform activity – a systematic review and meta-analysis of observational studiesMorphine in acute coronary syndrome: systematic review and meta-analysisManaging treatment fluctuations in Parkinson disease: "On" again-, "off" againAnti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Bilateral gigantic earlobe keloidsExtended daily dialysis versus intermittent hemodialysis for acute kidney injury: A systematic reviewBiofluid Biomarkers in Huntington's DiseaseMechanical Thrombectomy and Functional Outcomes After StrokeThe risks of converting post-hoc findings into primary outcomes in subsequent trialsHuntington's Disease Clinical Trials Corner: August 2018Deep brain stimulation for dystonia
P50
Q24185766-4C3531A5-6863-4EE5-9869-FB754799B4DEQ26752659-41A32CD5-290A-4913-9FBC-1643C56CA9FBQ30224292-A0A97169-9ECB-4DF1-8DB6-5643D9B7F2F1Q34556476-1B7B85BD-584A-444D-9B4D-7C8ED4154C85Q35650348-6EE5AABB-F809-4480-99E6-8607DDA9F103Q37471567-F22D41AF-7448-42AE-BC96-9E252720155EQ38635488-6406FB8D-6474-4D74-8CF9-19557CDF635AQ38697132-E2F1A7CD-6349-4CC7-88F8-C5F1CE8D4B9FQ38738106-D8BEBA44-C947-4B21-BBDE-DD4088E75FE4Q38744960-51D97AA1-8E55-43C4-AB25-77B476A8C839Q38943872-36B0629E-C5BE-4604-8772-09EAC9E53D40Q38990991-F78C130E-C737-4AF6-80E4-9667DF89154DQ39034803-A9359D16-EA95-4922-B823-94C8E3B8882FQ41540646-5FB0E7C3-7FFC-4DF7-B3B4-02A6696CC98EQ45305814-8B566967-4303-4BB5-BB10-C45FF035F6D9Q47123763-6D45FC2E-A155-4615-BE64-79D804098270Q47325788-B5D8B543-7FC1-43C6-A1C6-386D191075ECQ47841281-7AA269E8-FBFE-4657-B3F0-9B434BE1281EQ50060833-EB3AA694-3560-4964-BDD9-4A991FB8E72DQ50101029-26447446-7186-40DD-81B1-3D7B491A7ED0Q52640345-EAC4D02F-A176-4F5F-A98B-F68165EE34FFQ52663590-3BABE7FD-201D-4F5D-9627-E579E5351004Q52685687-738EF65E-005F-48B4-9817-BE46C685638AQ52987427-8688981B-0256-4754-BB52-231E007CF783Q53834994-9332B6E2-02C8-4CD0-8F33-ECBB59834820Q58574520-E74C3DB8-3D56-46A1-9679-5EBC4E789707Q58870298-06783672-18F6-4EBA-BD8C-F91097D34201Q58870300-4C32438B-D0CF-4AA4-840B-A64AE130481BQ59132032-5858E3E4-DDAD-425F-9BA8-475484B66878Q59270471-8EA6E34A-8360-4FCE-BACF-BD1492C57FB7Q64085919-44364FD5-7063-4672-9108-D0F00B7215B2Q64778246-A2674F47-8EFC-496A-AA2A-B96DAB87B3B2Q64937305-FA1B6366-32D7-4F6E-BEEA-78916478626DQ87204883-C900D4D5-9C2B-4E32-B699-5392389B591CQ87402822-B3AE5E02-F2A0-4582-A8F4-C97FD78893FDQ88946893-4E3FAEBD-6912-4138-A7B5-1DC001182DF5Q89298959-D955C71E-C7AD-4C50-B9B7-4648900C9578Q89521036-1EC0850C-7128-4206-B046-9B7E9EB3A334Q90920674-6F50A7F7-3B9F-4A0F-A1B4-86B973A95CA0Q90981538-BE729E24-B296-4FFA-9210-C862D5976961
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Filipe B. Rodrigues
@ast
Filipe B. Rodrigues
@en
Filipe B. Rodrigues
@es
Filipe B. Rodrigues
@nl
Filipe B. Rodrigues
@sl
type
label
Filipe B. Rodrigues
@ast
Filipe B. Rodrigues
@en
Filipe B. Rodrigues
@es
Filipe B. Rodrigues
@nl
Filipe B. Rodrigues
@sl
altLabel
Filipe B Rodrigues
@en
prefLabel
Filipe B. Rodrigues
@ast
Filipe B. Rodrigues
@en
Filipe B. Rodrigues
@es
Filipe B. Rodrigues
@nl
Filipe B. Rodrigues
@sl
P1153
P1053
R-2679-2017
P106
P1153
56689294100
57055016100
57191254295
P21
P31
P3829
P496
0000-0002-5567-7938